(1R,2R)-1,2-Cyclohexanedicarboxylic Acid Supply Chain Strategy
Mapping US20040054220A1 Patent Risks to (1R,2R)-1,2-Cyclohexanedicarboxylic Acid Technical Specifications
Procurement executives managing the supply chain for antipsychotic APIs must recognize that chemical specifications are not merely quality metrics; they are intellectual property safeguards. The synthesis pathway outlined in patent US20040054220A1 relies heavily on the stereochemical integrity of the starting materials. Specifically, the use of (1R,2R)-1,2-Cyclohexanedicarboxylic Acid (CAS: 46022-05-3) is critical for establishing the correct chiral centers in Lurasidone. Deviations in enantiomeric purity can invalidate the synthetic route, leading to costly reprocessing or regulatory rejection.
When evaluating a global manufacturer supply chain, technical due diligence must extend beyond standard purity assays. The risk profile increases if the supplier cannot demonstrate control over trace stereoisomers that may co-elute during standard GC analysis. Procurement teams should request chiral HPLC data specifically validating the absence of the (1S,2S) enantiomer, as even minor contamination can compromise the downstream stereochemistry. This level of specification alignment is necessary to maintain freedom to operate within the patented manufacturing process.
Defining Enantiomeric Purity Grades to Mitigate Supply Chain Rejection in Bulk Lurasidone Production
In the context of bulk Lurasidone production, the definition of "pharmaceutical grade" must be quantified by enantiomeric excess (ee) rather than general chemical purity. A standard industrial purity of ≥98.0% is insufficient if the remaining 2% consists of the wrong stereoisomer. Supply chain rejection often occurs at the API manufacturing stage when intermediates fail to meet the strict stereochemical thresholds required for FDA or EMA filings.
NINGBO INNO PHARMCHEM CO.,LTD. maintains rigorous control over these stereochemical parameters to support pharmaceutical partners. By defining grades based on chiral integrity rather than just assay percentage, manufacturers can mitigate the risk of batch failure during the final crystallization steps of the API. For detailed protocols on sourcing for Lurasidone synthesis, procurement managers should align their vendor qualification criteria with these specific stereochemical requirements to ensure seamless integration into the production line.
Auditing COA Parameters for Critical Quality Attributes in Global Manufacturer Supply Chains
A Certificate of Analysis (COA) for (1R,2R)-(-)-1,2-Cyclohexanedicarboxylic Acid typically lists standard parameters such as melting point and assay. However, experienced process engineers know that critical quality attributes (CQAs) often lie in non-standard parameters that affect processing behavior. For instance, while the melting point is typically observed at 184°C, the thermal degradation threshold during vacuum drying is a critical edge-case parameter. If the drying temperature exceeds specific limits during bulk handling, slight discoloration may occur due to thermal stress, affecting the visual specifications of the final API.
Furthermore, bulk density can shift significantly based on milling processes and ambient humidity during transit. We have observed that prolonged exposure to high humidity cycles during ocean freight can cause minor agglomeration, altering flowability properties during automated dispensing. These parameters are not always explicitly stated on a standard COA but are vital for process validation. The following table outlines the key technical parameters that should be audited during supplier qualification:
| Parameter | Standard Specification | Critical Control Limit |
|---|---|---|
| Molecular Weight | 172.18 | Fixed Constant |
| Assay (Purity) | ≥98.0% (GC,T) | ≥99.0% for API Start |
| Melting Point | 184°C | 182°C - 186°C |
| Enantiomeric Purity | Please refer to the batch-specific COA | ≥99.5% ee |
| Loss on Drying | Please refer to the batch-specific COA | ≤0.5% |
For a deeper understanding of cost implications related to these specifications, review our analysis on bulk price procurement strategies. Ensuring these parameters are locked in before production begins prevents costly deviations later in the supply chain.
Standardizing Bulk Packaging Integrity to Prevent Compliance Deviations During Transport
Physical packaging integrity is the first line of defense against quality deviations during global logistics. For crystalline powders like CAS 46022-05-3, moisture ingress is the primary risk factor. Standard packaging configurations should utilize multi-wall paper bags with polyethylene liners or 25kg fiber drums with sealed inner bags. The focus must remain on the physical barrier properties of the packaging rather than regulatory environmental claims.
During winter shipping conditions, temperature fluctuations can lead to condensation inside containers if the packaging is not adequately sealed. This moisture can initiate hydrolysis or clumping, rendering the material difficult to handle upon arrival. Procurement contracts should specify packaging tests such as drop tests and moisture vapor transmission rates (MVTR) for the liner material. Ensuring that the physical containment system matches the chemical sensitivity of the product is essential for maintaining the quality attributes defined in the COA throughout the logistics journey.
Correlating Synthesis Process Controls with Patent Landscapes for Secure Bulk Production
Secure bulk production requires correlating internal synthesis process controls with the external patent landscape. Manufacturers must ensure that their catalytic systems and resolution methods do not infringe on existing intellectual property while maintaining the yield and purity required for commercial viability. Process controls such as reaction temperature, solvent selection, and crystallization rates must be documented and validated.
Transparency in the synthesis route allows the buyer to assess potential supply chain disruptions related to raw material availability or patent litigation. A robust global manufacturer supply chain will provide audit trails that demonstrate compliance with the defined synthetic pathway without revealing proprietary trade secrets. This balance ensures that the supply of (1R,2R)-1,2-Cyclohexanedicarboxylic Acid remains stable and legally secure for long-term API production campaigns.
Frequently Asked Questions
What is the standard lead time for bulk orders of this intermediate?
Lead times vary based on current inventory levels and production scheduling. Please contact our sales team for a specific timeline based on your required quantity and destination.
Can you provide a sample for process validation before bulk procurement?
Yes, we support process validation with sample batches. Please refer to the batch-specific COA for the sample data to ensure it meets your technical requirements.
What packaging options are available for international shipping?
We offer standard 25kg fiber drums and multi-wall bags with PE liners. Custom packaging configurations can be discussed to meet specific logistics requirements.
How is enantiomeric purity verified during quality control?
Enantiomeric purity is verified using chiral HPLC methods. Specific retention times and separation factors are documented in the quality control records.
Sourcing and Technical Support
Establishing a reliable supply chain for chiral intermediates requires a partner who understands both the chemical nuances and the commercial pressures of pharmaceutical manufacturing. NINGBO INNO PHARMCHEM CO.,LTD. is committed to providing transparent technical data and stable supply capabilities for global partners. Our engineering team focuses on maintaining the physical and chemical integrity of every batch from production to delivery. For custom synthesis requirements or to validate our drop-in replacement data, consult with our process engineers directly.